These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27920580)

  • 1. Positive clinical outcomes derived from using
    Di Pierro F; Colombo M; Zanvit A; Rottoli AS
    Drug Healthc Patient Saf; 2016; 8():77-81. PubMed ID: 27920580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media.
    Di Pierro F; Donato G; Fomia F; Adami T; Careddu D; Cassandro C; Albera R
    Int J Gen Med; 2012; 5():991-7. PubMed ID: 23233809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children.
    Di Pierro F; Colombo M; Zanvit A; Risso P; Rottoli AS
    Drug Healthc Patient Saf; 2014; 6():15-20. PubMed ID: 24600248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of administration of Streptococcus salivarius K12 on the occurrence of streptococcal pharyngo-tonsillitis, scarlet fever and acute otitis media in 3 years old children.
    Di Pierro F; Colombo M; Giuliani MG; Danza ML; Basile I; Bollani T; Conti AM; Zanvit A; Rottoli AS
    Eur Rev Med Pharmacol Sci; 2016 Nov; 20(21):4601-4606. PubMed ID: 27874935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius.
    Tagg JR
    Indian J Med Res; 2004 May; 119 Suppl():13-6. PubMed ID: 15232154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Streptococcus salivarius K12 to reduce the incidence of pharyngo-tonsillitis and acute otitis media in children: a retrospective analysis in not-recurrent pediatric subjects.
    Di Pierro F; Risso P; Poggi E; Timitilli A; Bolloli S; Bruno M; Caneva E; Campus R; Giannattasio A
    Minerva Pediatr; 2018 Jun; 70(3):240-245. PubMed ID: 29322750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults.
    Di Pierro F; Adami T; Rapacioli G; Giardini N; Streitberger C
    Expert Opin Biol Ther; 2013 Mar; 13(3):339-43. PubMed ID: 23286823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Oral Probiotic Streptococcus salivarius K12 on Ear and Oral Cavity Health in Humans: Systematic Review.
    Zupancic K; Kriksic V; Kovacevic I; Kovacevic D
    Probiotics Antimicrob Proteins; 2017 Jun; 9(2):102-110. PubMed ID: 28236205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon Gamma Response in Human Saliva Following Exposure to the Oral Probiotic Streptococcus salivarius BLIS K12.
    Laws GA; Harold LK; Tagg JR; Hale JDF
    Probiotics Antimicrob Proteins; 2024 Feb; 16(1):93-98. PubMed ID: 36477439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Efficacy of BLIS-Producing Probiotic K12 for the Prevention of Group A Streptococcus Pharyngitis: a Short Communication.
    Di Pierro F
    Probiotics Antimicrob Proteins; 2019 Mar; 11(1):332-334. PubMed ID: 29464500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro Inhibition of Clinical Isolates of Otitis Media Pathogens by the Probiotic Streptococcus salivarius BLIS K12.
    Chen TY; Hale JDF; Tagg JR; Jain R; Voss AL; Mills N; Best EJ; Stevenson DS; Bird PA; Walls T
    Probiotics Antimicrob Proteins; 2021 Jun; 13(3):734-738. PubMed ID: 33179212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Oral Probiotic Streptococcus salivarius K12 on Group A Streptococcus Pharyngitis: A Pragmatic Trial in Schools.
    Doyle H; Pierse N; Tiatia R; Williamson D; Baker M; Crane J
    Pediatr Infect Dis J; 2018 Jul; 37(7):619-623. PubMed ID: 29189607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral use of Streptococcus salivarius K12 in children with secretory otitis media: preliminary results of a pilot, uncontrolled study.
    Di Pierro F; Di Pasquale D; Di Cicco M
    Int J Gen Med; 2015; 8():303-8. PubMed ID: 26396541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Streptococcal Bacteriocin-Like Inhibitory Substances: Some Personal Insights into the Bacteriocin-Like Activities Produced by Streptococci Good and Bad.
    Tagg JR
    Probiotics Antimicrob Proteins; 2009 Jun; 1(1):60-6. PubMed ID: 26783132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended Safety Data for the Oral Cavity Probiotic Streptococcus salivarius K12.
    Burton JP; Chilcott CN; Wescombe PA; Tagg JR
    Probiotics Antimicrob Proteins; 2010 Oct; 2(3):135-44. PubMed ID: 26781236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Systemic Immune Response to Ingestion of the Oral Probiotic Streptococcus salivarius BLIS K12.
    Laws GL; Hale JDF; Kemp RA
    Probiotics Antimicrob Proteins; 2021 Dec; 13(6):1521-1529. PubMed ID: 34282568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12.
    Hyink O; Wescombe PA; Upton M; Ragland N; Burton JP; Tagg JR
    Appl Environ Microbiol; 2007 Feb; 73(4):1107-13. PubMed ID: 17194838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacteriocin-like inhibitory substance (BLIS) production by the normal flora of the nasopharynx: potential to protect against otitis media?
    Walls T; Power D; Tagg J
    J Med Microbiol; 2003 Sep; 52(Pt 9):829-833. PubMed ID: 12909662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriotherapy with Streptococcus salivarius 24SMB and Streptococcus oralis 89a oral spray for children with recurrent streptococcal pharyngotonsillitis: a randomized placebo-controlled clinical study.
    Andaloro C; Santagati M; Stefani S; La Mantia I
    Eur Arch Otorhinolaryngol; 2019 Mar; 276(3):879-887. PubMed ID: 30767047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of group A beta-hemolytic streptococcus pharyngo-tonsillar infections associated with use of the oral probiotic Streptococcus salivarius K12: a retrospective observational study.
    Gregori G; Righi O; Risso P; Boiardi G; Demuru G; Ferzetti A; Galli A; Ghisoni M; Lenzini S; Marenghi C; Mura C; Sacchetti R; Suzzani L
    Ther Clin Risk Manag; 2016; 12():87-92. PubMed ID: 26855579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.